Skip to content

Study · Non-randomized trial · n = 5 · 2009

4 results

Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.

Harms JH, Lautenschlager S, Minder CE, Minder EI

Photochemistry and photobiology1 Nov 2009Cited by 35 (Europe PMC)

PMID19656325 (opens in a new tab)DOI10.1111/j.1751-1097.2009.00595.x (opens in a new tab)PepBankPUB-19656325
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In five patients with erythropoietic protoporphyria, afamelanotide implants increased tolerance to photoprovocation from Day 30 to Day 120 compared with baseline.

    In plain wordsIn five people with EPP, afamelanotide implants raised tolerance to a light test compared with before treatment.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseTolerance to photoprovocation
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    20 mg · subcutaneous sustained-release implant · two implants, 60-day intervalAs given in this study (human).

    Source sentences

    Summary
    From Day 30 to Day 120 tolerance to photoprovocation significantly increased compared with baseline (P = 0.007)
    2 context sentences
    Summary · context
    Therapeutic efficacy was assessed by a photoprovocation test using standardized white light irradiation, melanin density (MD) determination and daily recording of sunlight exposure and symptoms.
    Summary · context
    A sustained-release subcutaneous implant of 20 mg afamelanotide was administered twice, with a 60-day interval to five EPP patients.
  2. 02HumanNon-randomized trialEfficacy outcome

    In five patients with erythropoietic protoporphyria, skin melanin density was significantly higher than at baseline from Day 30 to Day 120 after afamelanotide implants.

    In plain wordsIn five people with EPP, skin melanin density was higher than before treatment after afamelanotide implants.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseSkin melanin density
    Study

    n = 5

    Comparator
    Baseline
    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    20 mg · subcutaneous sustained-release implant · two implants, 60-day intervalAs given in this study (human).

    Source sentences

    Summary
    From Day 30 to Day 120 tolerance to photoprovocation significantly increased compared with baseline (P = 0.007) and skin MD was significantly higher than that recorded at baseline (P = 0.004).
    1 context sentence
    Summary · context
    A sustained-release subcutaneous implant of 20 mg afamelanotide was administered twice, with a 60-day interval to five EPP patients.
  3. 03HumanNon-randomized trialEfficacy outcome

    In five patients with erythropoietic protoporphyria, no phototoxic events were recorded past Day 4 of afamelanotide treatment, apart from two low-grade pain episodes.

    In plain wordsIn five people with EPP, no phototoxic reactions were recorded after Day 4 of afamelanotide, apart from two mild pain episodes.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreasePhototoxic events
    Study

    n = 5

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    20 mg · subcutaneous sustained-release implant · two implants, 60-day intervalAs given in this study (human).

    Source sentences

    Summary
    Except for two low-grade pain episodes, patients recorded no phototoxic events past Day 4 of treatment.
    1 context sentence
    Summary · context
    A sustained-release subcutaneous implant of 20 mg afamelanotide was administered twice, with a 60-day interval to five EPP patients.
  4. 04HumanNon-randomized trialEfficacy outcome

    In five patients with erythropoietic protoporphyria, tolerance to natural sunlight was up to 24 times longer than before afamelanotide therapy.

    In plain wordsIn five people with EPP, time in sunlight without symptoms was up to 24 times longer than before afamelanotide.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseTolerance to natural sunlight
    Study

    n = 5

    Comparator
    Before therapy
    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    20 mg · subcutaneous sustained-release implant · two implants, 60-day intervalAs given in this study (human).

    Measurements

    tolerance to sunlight
    ≤ 24 times longer
    versus before therapy

    Source sentences

    Summary
    Tolerance to natural sunlight was up to 24 times longer than prior to therapy.
    1 context sentence
    Summary · context
    A sustained-release subcutaneous implant of 20 mg afamelanotide was administered twice, with a 60-day interval to five EPP patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.